Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic
20 Décembre 2019 - 3:00PM
Telo Genomics Corp. (TSX-V: TELO) (the
“
Company” or “
TELO”), is pleased
to announce that it has signed a collaboration agreement
with Mayo Clinic in Minnesota to conduct clinical studies to
evaluate and validate the utility of the Company’s proprietary
telomere analytics as a prognostic solution for Multiple Myeloma.
The collaboration studies will be led by Dr.
Shaji Kumar, MD, and were designed to include two retrospective
phases with the potential of a third prospective phase. For each
phase, TELO’s analytics will be employed to: 1) predict the
progression of multiple myeloma precursors to full stage multiple
myeloma, and 2) predict patient responses to first-line therapy at
the point of diagnosis.
Multiple Myeloma (“MM”) is a highly challenging
blood cancer that forms in plasma cells, a type of white blood cell
with an annual incidence rate of approximately 32,000 newly
diagnosed cases in North America and approximately 40,000 newly
diagnosed cases in Europe. MM is currently incurable but
patients may go into remission with treatment. MM is preceded
by an asymptomatic expansion of plasma cells, recognized as
monoclonal gammopathy of undetermined significance (“MGUS”) or
smoldering MM (“SMM”). Patients with MGUS or SMM are generally not
treated but monitored regularly to capture the onset of full stage
MM if the patient progresses. Once patients are diagnosed with
full stage MM they may be treated with several available treatment
regimens; however, it is estimated that 20% of the patients will
relapse on first line treatment within 12-15
months. Predicting patient progression from MGUS or SMM to
full stage myeloma, and predicting patient response to first line
therapy remain critical unmet needs in the clinic.
“Telo Genomics technology has shown promising
results in several academic studies focused on blood cancers
including Multiple Myeloma,” commented Dr. Kenneth Anderson,
Dana-Farber Cancer Institute, and member of TELO’s Clinical and
Scientific Advisory Board.
Phase 1 of the studies is expected to be
launched within the first quarter of 2020.
“We are excited to work with Dr. Kumar," said
Sherif Louis, CEO of Telo Genomics. “TELO’s board of directors has
identified Multiple Myeloma as a priority initiative for the
Company’s clinical programs, these studies are foundational to
advance TELO-MM tests towards commercialization.”
About Telo Genomics
Telo Genomics (TELO) is a world leader in the
quantitative analysis of telomeres, with a particular focus on
liquid biopsy diagnostics and prognostics. Its proprietary platform
technology has the potential to be a powerful healthcare tool to
improve the diagnosis and treatment of several cancers and
neurological diseases. TELO employs a proprietary software
platform, TeloView®, to precisely quantify specific features of
patient’s telomeres in three dimensions. This technology has been
successful in detecting early disease, determining the
aggressiveness and progression of disease and providing powerful
insights to guide therapy and treatment protocols, all of which
should contribute to improved clinical outcomes for patients. TELO
benefits from over 20 years of foundational and translational
academic research conducted by the Company’s founder providing a
wealth of more than 150 peer reviewed publications, 25 clinical
studies involving more than 3,000 patients and 20 different cancers
and Alzheimer’s disease.
For further information, please
contact:
Hugh
RogersChairman416-673-8487info@telodx.comMaRS Centre, South Tower,
101 College Street, Suite 200, Toronto, ON, M5G
1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“will”, or variations of such words and phrases or statements that
certain actions, events or results “will” occur. Forward-looking
statements regarding the consolidation, the offering, the use of
proceeds are based on the Company’s estimates and are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information, including capital expenditures and
other costs. There can be no assurance that such statements will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on forward-
looking statements and forward-looking information. The Company
will not update any forward-looking statements or forward-looking
information that are incorporated by reference herein, except as
required by applicable securities laws.
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024